Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Mystic Pharmaceuticals has received a Notice of Allowance from the US Patent Office for its 'Medical Devices For Dispensing Powders'.
Subscribe to our email newsletter
The company’s latest innovation provides patient self administration of drugs and biologics formulated as powders for systemic nasal, nose-to-brain, ophthalmic, sublingual and buccal routes of administration.
Mystic president and CEO Timothy Sullivan said drugs and biologics formulated, packaged and delivered as powders provide tremendous benefits for product stability and can eliminate the need for cold chain management.
"Our technology provides precision delivery of prescription medications utilizing low cost, mono-dose or multi-dose dispensers without the expense and complexity of volatile propellants," Sullivan said.
The company said that these latest advancements extend the capabilities of its VRx2 ‘unit of use’ packaging and delivery platform enabling the development of new classes of drug/device combination products and routes of non-invasive administration.
VersiDoser and VRx2 delivery technologies are used in combination with therapeutics to treat ocular, CNS, neurodegenerative and infectious diseases.